Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 181.24% is 2550% above its 5-year average of -7.40%, near the high end of its 5-year range (-67.11%–181.24%).
176.24% above its 12-month average of 65.61%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 11.85%.
RETURN ON ASSETS (ROA)
181.24%
RETURN ON ASSETS (ROA) AVG TTM
65.61%
RETURN ON ASSETS (ROA) AVG 3Y
3.99%
RETURN ON ASSETS (ROA) AVG 5Y
-7.40%
RETURN ON ASSETS (ROA) AVG 10Y
-9.87%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+176.24%
CURRENT VS 3Y AVG
+4436.67%
CURRENT VS 5Y AVG
+2549.74%
CURRENT VS 10Y AVG
+1935.93%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.37%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
+677.75%
vs the sector median at left
Kyntra Bio, Inc.
Market Cap
$24.09M
Return on Assets (ROA)
181.24%
TTM Avg
65.61%
3Y Avg
3.99%
5Y Avg
-7.40%
Market Cap
$24.68M
Return on Assets (ROA)
-40.73%
TTM Avg
-51.29%
3Y Avg
-88.21%
5Y Avg
-85.48%
Market Cap
$24.74M
Return on Assets (ROA)
-116.81%
TTM Avg
-53.20%
3Y Avg
-39.87%
5Y Avg
-35.95%
Market Cap
$23.04M
Return on Assets (ROA)
-75.43%
TTM Avg
-148.63%
3Y Avg
-74.35%
5Y Avg
-49.59%
Market Cap
$25.47M
Return on Assets (ROA)
-56.04%
TTM Avg
-32.94%
3Y Avg
-18.68%
5Y Avg
-12.05%
Market Cap
$22.36M
Return on Assets (ROA)
-248.63%
TTM Avg
-139.76%
3Y Avg
-97.50%
5Y Avg
-68.94%
Market Cap
$22.11M
Return on Assets (ROA)
-13.57%
TTM Avg
-12.25%
3Y Avg
-12.55%
5Y Avg
-25.19%
Market Cap
$21.76M
Return on Assets (ROA)
-228.73%
TTM Avg
-145.44%
3Y Avg
-152.25%
5Y Avg
-187.73%
Market Cap
$20.80M
Return on Assets (ROA)
-173.14%
TTM Avg
-158.95%
3Y Avg
-120.45%
5Y Avg
-102.27%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyntra Bio, Inc. (KYNB) | $24.09M | 181.24% | 65.61% | 3.99% | -7.40% |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.68M | -40.73% | -51.29% | -88.21% | -85.48% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.74M | -116.81% | -53.20% | -39.87% | -35.95% |
| Rein Therapeutics Inc. (RNTX)vs › | $23.04M | -75.43% | -148.63% | -74.35% | -49.59% |
| iTonic Holdings Ltd. (ITOC)vs › | $25.47M | -56.04% | -32.94% | -18.68% | -12.05% |
| LeonaBio, Inc. (LONA)vs › | $22.36M | -248.63% | -139.76% | -97.50% | -68.94% |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.11M | -13.57% | -12.25% | -12.55% | -25.19% |
| Modular Medical, Inc. (MODD)vs › | $21.76M | -228.73% | -145.44% | -152.25% | -187.73% |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.80M | -173.14% | -158.95% | -120.45% | -102.27% |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.74M | -22.11% | -50.36% | -51.04% | -41.44% |
ROA
181.2%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 153.40% |
| 2024-12-31 | -22.18% |
| 2023-12-31 | -67.11% |
| 2022-12-31 | -48.13% |
| 2021-12-31 | -37.48% |
| 2020-12-31 | -22.89% |
| 2019-12-31 | -8.98% |
| 2018-12-31 | -9.81% |
| 2017-12-31 | -14.04% |
| 2016-12-31 | -13.14% |
| 2015-12-31 | -18.23% |
| 2014-12-31 | -12.31% |
| 2013-12-31 | -5.03% |
| 2012-12-31 | -12.26% |
